- Ustekinumab, a monoclonal antibody targeting interleukin-12 and interleukin-23, has become a vital component in the treatment of immune-mediated inflammatory diseases such as plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Its targeted mechanism of action offers patients long-term remission, reduced flare-ups, and improved quality of life, establishing it as a preferred biologic therapy in both hospital and specialty care settings
- The escalating demand for Ustekinumab is primarily driven by the growing prevalence of chronic autoimmune disorders, increasing awareness among patients and physicians, and the expanding accessibility of advanced biologic therapies across emerging markets. In addition, the shift toward personalized medicine and real-world evidence supporting Ustekinumab’s efficacy and safety further strengthens its adoption
- North America dominated the Ustekinumab market with the largest revenue share of 22.4% in 2024, attributed to the high incidence of inflammatory bowel disease and psoriasis, robust reimbursement frameworks, and early adoption of biologic therapies. The United States, in particular, leads the region due to strong clinical infrastructure, high treatment awareness, and a concentration of key biopharmaceutical players actively promoting long-term therapy adherence
- Asia-Pacific is expected to be the fastest-growing region in the ustekinumab market during the forecast period, owing to increasing urbanization, rising disposable incomes, greater healthcare access, and growing diagnosis rates for autoimmune diseases. Countries such as China, Japan, and India are witnessing significant investments in biologic drug infrastructure and regulatory acceleration, fostering market expansion
- The Adult segment dominated the ustekinumab market, with the market share of 85.1% in 2024, driven by the high incidence of psoriasis and Crohn’s disease among adults and established clinical evidence supporting ustekinumab’s long-term safety and efficacy in this population
